• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于左氧氟沙星的三线疗法根除消化性溃疡疾病中幽门螺杆菌的疗效。 (你原文中“of the Eradication of in Peptic Ulcer Disease”这里少了个关键单词,比如“Helicobacter pylori”之类的,我按照常见情况补充完整翻译了,你可根据实际情况调整)

Efficacy of Levofloxacin-Based Third-Line Therapy for the Eradication of in Peptic Ulcer Disease.

作者信息

Lim Joo Hyun, Kim Sang Gyun, Song Ji Hyun, Hwang Jae Jin, Lee Dong Ho, Han Jae Pil, Hong Su Jin, Kim Ji Hyun, Jeon Seong Woo, Kim Gwang Ha, Shim Ki-Nam, Shin Woon Geon, Kim Tae Ho, Kim Sun Moon, Chung Il-Kwon, Kim Hyun-Soo, Kim Heung Up, Lee Joongyub, Kim Jae Gyu

机构信息

Department of Internal Medicine, Seoul National University Hospital, Healthcare System Gangnam Center, Healthcare Research Institute, Seoul, Korea.

Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.

出版信息

Gut Liver. 2017 Mar 15;11(2):226-231. doi: 10.5009/gnl16099.

DOI:10.5009/gnl16099
PMID:
27609487
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5347646/
Abstract

BACKGROUND/AIMS: The resistance rate of is gradually increasing. We aimed to evaluate the efficacy of levofloxacin-based third-line eradication in peptic ulcer disease.

METHODS

Between 2002 and 2014, 110 patients in 14 medical centers received levofloxacin-based third-line eradication therapy for peptic ulcer disease. Of these, 88 were included in the study; 21 were excluded because of lack of follow-up and one was excluded for poor compliance. Their eradication rates, treatment regimens and durations, and types of peptic ulcers were analyzed.

RESULTS

The overall eradiation rate was 71.6%. The adherence rate was 80.0%. All except one received a proton-pump inhibitor, amoxicillin, and levofloxacin. One received a proton-pump inhibitor, amoxicillin, levofloxacin, and clarithromycin, and the eradication was successful. Thirty-one were administered the therapy for 7 days, 25 for 10 days, and 32 for 14 days. No significant differences were observed in the eradication rates between the three groups (7-days, 80.6% vs 10-days, 64.0% vs 14-days, 68.8%, p=0.353). Additionally, no differences were found in the eradiation rates according to the type of peptic ulcer (gastric ulcer, 73.2% vs duodenal/gastroduodenal ulcer, 68.8%, p=0.655).

CONCLUSIONS

Levofloxacin-based third-line eradication showed efficacy similar to that of previously reported first/second-line therapies.

摘要

背景/目的:[某种细菌]的耐药率正在逐渐上升。我们旨在评估以左氧氟沙星为基础的三线[细菌]根除疗法在消化性溃疡疾病中的疗效。

方法

2002年至2014年期间,14个医疗中心的110例患者接受了以左氧氟沙星为基础的三线消化性溃疡疾病根除治疗。其中,88例被纳入研究;21例因缺乏随访而被排除,1例因依从性差而被排除。分析了他们的根除率、治疗方案和疗程以及消化性溃疡的类型。

结果

总体根除率为71.6%。依从率为80.0%。除1例患者外,所有患者均接受了质子泵抑制剂、阿莫西林和左氧氟沙星治疗。1例患者接受了质子泵抑制剂、阿莫西林、左氧氟沙星和克拉霉素治疗,且根除成功。31例患者接受了7天的治疗,25例接受了10天的治疗,32例接受了14天的治疗。三组之间的根除率无显著差异(7天组为80.6%,10天组为64.0%,14天组为68.8%,p = 0.353)。此外,根据消化性溃疡的类型,根除率也没有差异(胃溃疡为73.2%,十二指肠溃疡/胃十二指肠溃疡为68.8%,p = 0.655)。

结论

以左氧氟沙星为基础的三线[细菌]根除疗法显示出与先前报道的一线/二线疗法相似的疗效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9e4/5347646/a6bb1a2f5417/gnl-11-226f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9e4/5347646/a6bb1a2f5417/gnl-11-226f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9e4/5347646/a6bb1a2f5417/gnl-11-226f1.jpg

相似文献

1
Efficacy of Levofloxacin-Based Third-Line Therapy for the Eradication of in Peptic Ulcer Disease.基于左氧氟沙星的三线疗法根除消化性溃疡疾病中幽门螺杆菌的疗效。 (你原文中“of the Eradication of in Peptic Ulcer Disease”这里少了个关键单词,比如“Helicobacter pylori”之类的,我按照常见情况补充完整翻译了,你可根据实际情况调整)
Gut Liver. 2017 Mar 15;11(2):226-231. doi: 10.5009/gnl16099.
2
Efficacy of levofloxacin, amoxicillin and a proton pump inhibitor in the eradication of Helicobacter pylori in Brazilian patients with peptic ulcers.左氧氟沙星、阿莫西林和质子泵抑制剂对巴西消化性溃疡患者根除幽门螺杆菌的疗效。
Clinics (Sao Paulo). 2015 May;70(5):318-21. doi: 10.6061/clinics/2015(05)02. Epub 2015 May 1.
3
Safety and efficacy of 1-week levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori-related peptic ulcer disease in Kashmir, India.基于左氧氟沙星的一周三联疗法在印度克什米尔地区幽门螺杆菌相关性消化性溃疡疾病一线治疗中的安全性和有效性
Indian J Gastroenterol. 2013 Jan;32(1):32-6. doi: 10.1007/s12664-012-0285-y. Epub 2012 Dec 8.
4
Second-line levofloxacin-based triple therapy's efficiency for Helicobacter pylori eradication in patients with peptic ulcer.二线基于左氧氟沙星的三联疗法对消化性溃疡患者根除幽门螺杆菌的疗效。
South Med J. 2011 Aug;104(8):579-83. doi: 10.1097/SMJ.0b013e3182249be0.
5
Follow-up survey of a large-scale multicenter, double-blind study of triple therapy with lansoprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients.在日本消化性溃疡患者中,使用兰索拉唑、阿莫西林和克拉霉素三联疗法根除幽门螺杆菌的大规模多中心双盲研究的随访调查。
J Gastroenterol. 2003;38(4):339-47. doi: 10.1007/s005350300061.
6
A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients.一项关于兰索拉唑、阿莫西林和克拉霉素三联疗法根除日本消化性溃疡患者幽门螺杆菌的多中心、双盲研究。
Helicobacter. 2001 Sep;6(3):254-61. doi: 10.1046/j.1523-5378.2001.00037.x.
7
Levofloxacin or Clarithromycin-based quadruple regimens: what is the best alternative as first-line treatment for Helicobacter pylori eradication in a country with high resistance rates for both antibiotics?基于左氧氟沙星或克拉霉素的四联疗法:在两种抗生素耐药率都很高的国家,作为根除幽门螺杆菌的一线治疗,哪种是最佳替代方案?
BMC Gastroenterol. 2017 Feb 15;17(1):31. doi: 10.1186/s12876-017-0589-6.
8
Efficacy of a therapeutic strategy for eradication of Helicobacter pylori infection.根治幽门螺杆菌感染的治疗策略的疗效。
World J Gastroenterol. 2012 Sep 7;18(33):4542-8. doi: 10.3748/wjg.v18.i33.4542.
9
The efficacy of levofloxacin-based triple therapy for first-line helicobacter pylori eradication.基于左氧氟沙星的三联疗法用于一线根除幽门螺杆菌的疗效。
Med Arch. 2013;67(5):348-50. doi: 10.5455/medarh.2013.67.348-350.
10
4-day triple therapy with rabeprazole, amoxicillin and clarithromycin in the eradication of Helicobacter pylori in patients with peptic ulcer disease--A pilot study.雷贝拉唑、阿莫西林和克拉霉素4天三联疗法根除消化性溃疡疾病患者幽门螺杆菌的一项初步研究。
Z Gastroenterol. 2001 Apr;39(4):279-81, 284-5. doi: 10.1055/s-2001-12873.

引用本文的文献

1
[Approach to Patients with Consecutive Eradication Failure].[连续根除失败患者的处理方法]
Korean J Helicobacter Up Gastrointest Res. 2023 Mar;23(1):15-21. doi: 10.7704/kjhugr.2023.0017. Epub 2023 Mar 9.
2
Association between failed eradication of 7-day triple therapy for Helicobacter pylori and untreated dental caries in Japanese adults.日本成年人幽门螺杆菌 7 天三联疗法根除失败与未治疗的龋齿之间的关系。
Sci Rep. 2024 Feb 19;14(1):4043. doi: 10.1038/s41598-024-54757-8.
3
Trends in -related gastric ulcer research from 2012 to 2022: A bibliometric and visual analysis.

本文引用的文献

1
Eradication Rates of Helicobacter pylori in Korea Over the Past 10 years and Correlation of the Amount of Antibiotics Use: Nationwide Survey.过去10年韩国幽门螺杆菌根除率及抗生素使用量的相关性:全国性调查
Helicobacter. 2016 Aug;21(4):266-78. doi: 10.1111/hel.12279. Epub 2015 Oct 16.
2
High Helicobacter pylori cure rate with sitafloxacin-based triple therapy.基于西他沙星的三联疗法对幽门螺杆菌的治愈率高。
Aliment Pharmacol Ther. 2015 Aug;42(4):477-83. doi: 10.1111/apt.13280. Epub 2015 Jun 15.
3
Comparison of efficacy and safety of levofloxacin-containing versus standard sequential therapy in eradication of Helicobacter pylori infection in Korea.
2012年至2022年与胃溃疡相关的研究趋势:文献计量与可视化分析
Front Med (Lausanne). 2022 Nov 23;9:1027534. doi: 10.3389/fmed.2022.1027534. eCollection 2022.
4
Evidence based guidelines for the treatment of Helicobacter pylori infection in Korea 2020.韩国 2020 年幽门螺杆菌感染治疗的循证指南。
Korean J Intern Med. 2021 Jul;36(4):807-838. doi: 10.3904/kjim.2020.701. Epub 2021 Jun 8.
5
Treatment of Refractory Infection-Tailored or Empirical Therapy.难治性感染的治疗:个体化或经验性治疗。
Gut Liver. 2022 Jan 15;16(1):8-18. doi: 10.5009/gnl20330.
6
Role of Antimicrobial Susceptibility Testing before First-Line Treatment Containing Clarithromycin for Eradication in the Clinical Setting.在临床环境中,含克拉霉素的一线治疗用于根除之前进行抗菌药物敏感性测试的作用。
Antibiotics (Basel). 2021 Feb 21;10(2):214. doi: 10.3390/antibiotics10020214.
7
Evidence-Based Guidelines for the Treatment of Infection in Korea 2020.2020 年韩国感染治疗循证指南。
Gut Liver. 2021 Mar 15;15(2):168-195. doi: 10.5009/gnl20288.
8
Discovery of a Novel Mutation in DNA Gyrase and Changes in the Fluoroquinolone Resistance of over a 14-Year Period: A Single Center Study in Korea.14年间DNA回旋酶新突变的发现及氟喹诺酮耐药性的变化:韩国一项单中心研究
Antibiotics (Basel). 2020 May 27;9(6):287. doi: 10.3390/antibiotics9060287.
9
Efficacy of two different dosages of levofloxacin in curing Helicobacter pylori infection: A Prospective, Single-Center, randomized clinical trial.两种不同剂量左氧氟沙星治疗幽门螺杆菌感染的疗效:一项前瞻性、单中心、随机临床试验。
Sci Rep. 2018 Jun 13;8(1):9045. doi: 10.1038/s41598-018-27482-2.
含左氧氟沙星的序贯疗法与标准序贯疗法根除韩国幽门螺杆菌感染的疗效和安全性比较
Dig Liver Dis. 2015 Feb;47(2):114-8. doi: 10.1016/j.dld.2014.10.014. Epub 2014 Nov 15.
4
Meta-analysis of first-line triple therapy for helicobacter pylori eradication in Korea: is it time to change?韩国一线三联疗法根除幽门螺杆菌的荟萃分析:是否是时候改变了?
J Korean Med Sci. 2014 May;29(5):704-13. doi: 10.3346/jkms.2014.29.5.704. Epub 2014 Apr 25.
5
Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition.《2013年修订版韩国幽门螺杆菌感染诊断和治疗指南》
J Gastroenterol Hepatol. 2014;29(7):1371-86. doi: 10.1111/jgh.12607.
6
Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan.日本幽门螺杆菌根除三线标准治疗方案的多中心随机对照研究。
J Gastroenterol. 2013 Oct;48(10):1128-35. doi: 10.1007/s00535-012-0731-8. Epub 2013 Jan 11.
7
Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012.2003 年至 2012 年韩国幽门螺杆菌原发性和继发性抗菌耐药率。
Helicobacter. 2013 Jun;18(3):206-14. doi: 10.1111/hel.12031. Epub 2012 Dec 13.
8
Rifaximin Plus Levofloxacin-Based Rescue Regimen for the Eradication of Helicobacter pylori.利福昔明联合左氧氟沙星补救方案根除幽门螺杆菌。
Gut Liver. 2012 Oct;6(4):452-6. doi: 10.5009/gnl.2012.6.4.452. Epub 2012 Oct 18.
9
Levofloxacin/amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second-line.左氧氟沙星/阿莫西林为基础的方案与四联疗法在二线治疗幽门螺杆菌根除的比较。
World J Gastroenterol. 2012 Oct 28;18(40):5669-78. doi: 10.3748/wjg.v18.i40.5669.
10
[Comparison of rifabutin- and levofloxacin-based third-line rescue therapies for Helicobacter pylori].基于利福布汀和左氧氟沙星的幽门螺杆菌三线挽救治疗的比较
Korean J Gastroenterol. 2012 Jun 25;59(6):401-6. doi: 10.4166/kjg.2012.59.6.401.